💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Ex-Insys employees plead not guilty in U.S. drug-kickback case

Published 08/17/2016, 06:07 PM
© Reuters. Jonathan Roper Fernando Serrano walk with Serrano’s lawyer Jude Cardenas after they pleaded not guilty in Manhattan New York
LNKD
-

By Nate Raymond

NEW YORK (Reuters) - Two former Insys Therapeutics Inc employees pleaded not guilty on Wednesday to charges that they engaged in a scheme to pay doctors kickbacks including speaker fees to prescribe a drug containing the opioid fentanyl.

Jonathan Roper, a former Insys district sales manager, and Fernando Serrano, a former sales representative, entered their pleas in Manhattan federal court to charges including that they violated the federal Anti-Kickback Statute.

Their pleas followed their arrests in June and came amid various probes involving Insys and its fentanyl-based sublingual spray Subsys as U.S. law enforcement seek to combat a national opioid abuse epidemic.

Insys, based in Arizona, is not identified by name in the indictment against Roper, of Commack, New York, and Serrano, of Manalapan, New Jersey.

But details in the charging papers about the company and drug match Insys and Subsys. A LinkedIn (NYSE:LNKD) profile for Serrano shows he previously worked for Insys.

Insys did not respond to requests for comment.

Subsys, which Insys launched in 2012, is a spray approved for managing pain in cancer patients that contains fentanyl, a highly-addictive and regulated synthetic opioid. It generated $329.5 million in net revenue in 2015.

Prosecutors said that to market the spray, Insys established a program in which it paid doctors to act as speakers at educational presentations targeting healthcare professionals.

But prosecutors said many of the programs Roper and Serrano organized were social gatherings at high-end Manhattan restaurants where no education about the spray took place and where audience sign-in sheets contained forged signatures.

Both men were involved in organizing speaker programs for two Manhattan doctors who in 2014 were among the largest prescribers of the spray while earning $147,000 and $112,000 each in speaker fees, the indictment said.

The indictment said Roper and Serrano also were involved in paying for undisclosed alcoholic drinks and meals for doctors.

In court, Assistant U.S. Attorney Noah Solowiejczyk said more charges could be brought.

"The government is continuing to investigate," he said.

Insys has said that it has received information requests or subpoenas from eight other U.S. Attorneys' offices outside of Manhattan regarding doctors it had interacted with.

Those charged include a Connecticut nurse practitioner who in 2015 pleaded guilty to violating the kickback law, and an ex-Insys sales representative in Alabama who pleaded guilty in February to conspiring to violate the statute.

Insys also faces other state and federal investigations related to Subsys including into its sales and marketing practices.

© Reuters. Jonathan Roper Fernando Serrano walk with Serrano’s lawyer Jude Cardenas after they pleaded not guilty in Manhattan New York

The case is U.S. v. Roper et al, U.S. District Court, Southern District of New York, No. 16-cr-00542.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.